Tekrardan Hoşgeldiniz
Cointime’a Katıl
Giriş Yap
Kayıt Ol
Gelen kutunuzu kontrol edin
Merrimack Pharmaceuticals
About
Merrimack Pharmaceuticals discovers, designs and develops therapies for the treatment of diseases in the areas of autoimmunity and cancer.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Debt
- Last Funding Money Raised
- $25M
- Industries
- Biotechnology,Health Care,Pharmaceutical
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
Merrimack Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, design, and development of therapies for the treatment of diseases in the areas of autoimmunity and cancer. It develops MM-093, a human alpha-fetoprotein for the treatment of patients with rheumatoid arthritis and psoriasis; and MM-121, a human monoclonal antibody and therapeutic to block signaling of the ErbB3 receptor. Merrimack Pharmaceuticals, Inc. was formerly known as Atlantic BioPharmaceuticals, Inc. The company was founded in 1993 and is based in Cambridge, Massachusetts.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 2, 2018 | Post-IPO Debt | $25M | 1 |
Hercules Capital
|
— | Detail |
| Apr 14, 2011 | Private Equity（PE） | $77M | 1 | — | — | Detail |
| Apr 3, 2006 | Series E | $65M | 1 | — | — | Detail |
| Jun 20, 2005 | Debt Financing | $9M | 1 |
Hercules Capital
|
— | Detail |
| Apr 20, 2005 | Series D | $28.30M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Hercules Capital
|
Yes | Post-IPO Debt |
National Institutes of Health
|
Yes | Grant |
|
|
— | Private Equity（PE） |
|
|
— | Series C |
